2
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
37
Gastrointestinal
20
Dermatologic
17
Thoracic
12
Gynecologic
9
Genitourinary
9
Breast
4
Other solid neoplasm
2
Lymphoid
2
Sarcoma
1
Other
1
NET
1
Endocrine
1
Conditions
Obesity
410
Neoplasms
151
Mucositis
128
Sexual Dysfunction, Physiological
105
Breast Neoplasms
105
Polycystic Ovary Syndrome
98
Overweight
98
Dyspnea
62
Constipation
57
Motor Activity
54
Head and Neck Neoplasms
47
Prostatic Neoplasms
42
Weight Loss
39
Diabetes Mellitus
36
Pain
34
Colorectal Neoplasms
33
Endometrial Neoplasms
29
Stomatitis
28
Opioid-Induced Constipation
28
Lung Neoplasms
28
Depression
26
Diabetes Mellitus, Type 2
24
Cardiovascular Diseases
23
Obesity, Morbid
22
Multiple Endocrine Neoplasia Type 1
22
Insulin Resistance
22
Precursor Cell Lymphoblastic Leukemia-Lymphoma
21
Anxiety Disorders
21
Hypertension
19
Sexual Dysfunctions, Psychological
18
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms, Squamous Cell
×
Other
×
Clear all
NCT01283906
2013-09-12
MuGard
Access Pharmaceuticals, Inc.
Phase 4
Completed
120 enrolled